Stella Maris Therapeutics

Stella Maris Therapeutics is a biotechnology-focused company that develops and provides butyrate supplements to support gut and brain health. The company utilizes scientific research on the gut-brain axis to create innovative postbiotic solutions. Its flagship product is a high-quality, sodium-based butyrate supplement formulated with a specialized encapsulation strategy, using cellulose and gellan gum to ensure the compound reaches the colon, where it can be effectively utilized by intestinal cells to strengthen the gut barrier and reduce inflammation.

Founded by Dr. Daniel Czyz, an associate professor who studies microbial pathogenesis and neurodegenerative diseases, the company focuses on improving outcomes for individuals dealing with chronic inflammatory and neurodegenerative conditions, including Parkinson’s disease, inflammatory bowel disease, and rheumatoid arthritis. By combining rigorous quality control with a commitment to building relationships with patients and customers, Stella Maris Therapeutics aims to offer evidence-based wellness solutions that address the communication between the digestive system and the nervous system.